Companies Directory

Kancelaria świadczy usługi prawne w zakresie prawa gospodarczego, cywilnego, administracyjnego, budowlanego. Oferujemy również wsparcie w obszarze ochrony danych osobowych oraz compliance. Wśród Klientów kancelarii znajdują się firmy z branży nowych technologii, funduszy inwestycyjnych, medycznej. Jesteśmy nowoczesną kancelarią wspierającą nie tylko duże podmioty korporacyjne, ale również startupy. Naszym celem jest zapewnienie Klientom usług prawnych o najwyższej jakości. Bogate doświadczenie w obsłudze prawnej pozwala nam znaleźć optymalne rozwiązanie każdego biznesowego wyzwania.

kancellar.hu is one of Hungary’s leading information security consulting company. As to our philosophy we agree with writer Károly Balla D.: „Versatility is somehow ambiguos; more of a weakness than a virtue. One who is competent in everything is not really competent in anything.” kancellar.hu is dealing solely with information security however doing that in a holistic and vendor independent way.

Kancera is a Swedish based biotechnology company that is developing a new class of small molecule drugs based on the fractalkine system. Fractalkine is a master regulator that controls immune cells and cancer cells with precision and therefore can play a crucial role to treat acute excessive inflammation and treatment resistant cancers. Kancera's lead drug candidate KAND567 is currently studied in a phase II trial to address the cardiac-protective effect of KAND567 following myocardial infarction. Kancera has also announced its intention to start a phase I/II study of KAND567 in ovarian cancer in the beginning of 2023. The stock is traded on the Nasdaq First North Premier Growth Market.

Kancera is a Swedish based biotechnology company that is developing a new class of small molecule drugs based on the fractalkine system. Fractalkine is a master regulator that controls immune cells and cancer cells with precision and therefore can play a crucial role to treat acute excessive inflammation and treatment resistant cancers. Kancera's lead drug candidate KAND567 is currently studied in a phase II trial to address the cardiac-protective effect of KAND567 following myocardial infarction. Kancera has also announced its intention to start a phase I/II study of KAND567 in ovarian cancer in the beginning of 2023. The stock is traded on the Nasdaq First North Premier Growth Market.

Kanchansobha offers a complete suite of investment banking solutions to its clients. These include M&A Advisory, Corporate Finance Consultancy, Fund Raising (Debt and Equity), Corporate Debt Restructuring, Project Financing and Private Equity and Venture Capital Funding Solutions.

At Kanda, we’re more than a care provider - we’re a community. With decades of experience, we deliver tailored support solutions that embrace the complexity of life. From disability and NDIS support, to children, youth, and family services, aged home care, veterans' care and community nursing, our purpose is to empower individuals and create opportunities for a better quality of life. Previously known as Southern Cross Support Services (SCSS) and Programmed Care, we have been delivering support services to Australians for decades.